Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsRole of endoplasmic reticulum stress in drug-induced toxicityThe antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouseAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineChronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin ResistanceSecond generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Pharmacological treatment for generalized anxiety disorder in adults: an update.Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female MacaqueMetabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychoticsMetabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation AntipsychoticsAdiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug TreatmentAcute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.Brain stem as a target site for the metabolic side effects of olanzapinePolygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.Unraveling the mechanisms underlying olanzapine-induced insulin resistance.Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.Role of atypical antipsychotics in the treatment of generalized anxiety disorder.The reappraisal of benzodiazepines in the treatment of anxiety and related disorders.Type 2 diabetes in children and adolescents on atypical antipsychotics.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort.The cardiometabolic health nurse: physical health behaviour outcomes from a randomised controlled trial.Dietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain.Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Nurse-assessed metabolic monitoring: a file audit of risk factor prevalence and impact of an intervention to enhance measurement of waist circumference.Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis.Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies.Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis.The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance.Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders StudyRehabilitation to prevent premature mortality among people with serious mental illness
P2860
Q26747123-E7B05B03-26E3-4E4D-87E4-0B28D17FB0BFQ26765518-E955C643-29D3-4EDB-8199-C7AEC60B93BAQ28542712-177AC84E-236A-4BF0-A5E8-4A66C9F11621Q28543222-FA981FB3-5713-4395-9DBF-ECECB29FB60AQ28555023-9281C362-3661-4C87-B2D3-7DB18A822DA0Q34376884-51C62513-55B9-4053-A9F3-F27980C5807AQ34484276-592D3348-1F5C-447F-A7F9-1DAB0BC27F99Q34993531-C252D4FE-16C5-4AC3-8014-3157E717D3FDQ35330607-35136D90-5C65-448A-BD45-8CED75974EA5Q36005869-075DE69B-672C-429F-A7F1-F495DD600B26Q36060420-D443C63A-7F3C-4075-B345-6758DB22B31AQ36371905-5FE3C544-6A6C-43DF-A95B-30A3F50B4852Q36729872-42ED2F3E-B9DA-4AFB-B456-AE928C620673Q36784390-38A567A8-04EE-4666-BFA9-DC3165679406Q37110611-99985CA6-E8E4-474F-95C8-D1C6C3B93CE9Q37698621-3D9824D1-D0CB-46D2-A45C-A18804BFEE58Q38170310-389645F0-B53F-49F7-992B-7008FF13CB42Q38209188-7C3550A5-76D4-4CD9-A412-83D2E43A2231Q38252986-A18D4753-D307-4663-B02A-757988DFA1F5Q38530458-03BF50F9-0FBA-4770-B758-290E5233EC7EQ38708352-4859619C-E040-4D5B-B4C7-181423274211Q39051295-E0F59243-0F4D-40AD-B581-EBCF2E46246EQ39122661-53D9489C-CDB8-40C3-92F6-C9E4F892C204Q41703341-0A897918-1CCE-4174-AB05-537BACEFA89FQ42266399-67409C6D-7245-468F-8B69-B9394F21B860Q43090127-5DA81DC8-6778-4715-B8C8-B51E7C2FB9EBQ44464148-47CB6B73-1416-4A08-B6DA-1B0B0CD7F096Q46668444-67965601-9A1E-410B-82FC-A650F293FB06Q47165661-C7CAEDEF-F7B6-4797-9385-EF15D4AB1937Q47596558-1FB247EE-73F7-47EC-B218-7553250BE71EQ47605999-2C88D344-D63D-4DB3-A049-EA90016E6A2AQ47753742-DED8DB45-D2B3-44B0-9F21-A6E48C7E006CQ49481418-582A71D7-6AAE-475B-B309-1DAC908AC7D4Q49917593-837FAB03-A6C3-477E-AD9E-4960AD8292BEQ50079662-B81D14CE-05B2-4A37-B72F-8EABF9399147Q50096809-04AAA06C-51BA-45E5-B386-6B34AE439530Q53689686-C5EC3C90-1D5B-45BB-9835-F4F306639297Q55231596-C40CE559-B672-496F-9B69-ABC05298A45FQ57164581-892CDF8D-78C4-40F4-BA27-52702116AEB8Q57776202-2567498F-8EB2-48E1-8E3B-FEA50608EBD5
P2860
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@en
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@nl
type
label
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@en
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@nl
prefLabel
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@en
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@nl
P2093
P2860
P356
P1433
P1476
Antipsychotic-induced insulin ...... t gain or psychiatric disease.
@en
P2093
Carissa Fuller
Huong-Lan Nguyen
Joanna Grudziak
Karen L Teff
Karl Rickels
Michael R Rickels
P2860
P304
P356
10.2337/DB13-0430
P407
P577
2013-07-08T00:00:00Z